Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Isatuximab-dexamethasone

Phase 2Small molecule

EEMN Trial Office S.r.l. Impresa Sociale

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed Multiple MyelomaActive, not recruiting

Relapsed Multiple MyelomaPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Relapsed Multiple Myeloma

NCT04965155

Clinical

Trials by Indication[1]

Relapsed Multiple Myeloma1 trial

Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel Study)

Active, not recruiting·EEMN Trial Office S.r.l. Impresa Sociale·Phase 2·NCT04965155·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Isatuximab-dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isatuximab-dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isatuximab-dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMN Trial Office S.r.l. Impresa Sociale company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEMN Trial Office S.r.l. Impresa Sociale

Related News